微信分享
Vaccine Innovation Forum World 2025-中文站点

使用微信扫一扫分享到朋友圈

活动分享
Vaccine Innovation Forum World 2025-中文站点

使用微信扫一扫进入小程序分享活动

活动详情

VIF World 2025, the Vaccine Innovation Forum, stands as a premier international event dedicated to the advancement of vaccine science and global health. Building on the tremendous success of previous forums, including the groundbreaking VIF World 2024 in Shanghai, this year’s conference aims to further cement its reputation as a crucial meeting place for experts, researchers, policymakers, and industry leaders.

 

科学顾问委员会

Vaccine Innovation Forum World 2025-中文站点

Vaccine Innovation Forum World 2025-中文站点

Vaccine Innovation Forum World 2025-中文站点

Vaccine Innovation Forum World 2025-中文站点

Vaccine Innovation Forum World 2025-中文站点

Vaccine Innovation Forum World 2025-中文站点

0824342411808170.png往届照片


0707129801808170.jpg


关键议题

Novel Vaccine Innovation:

Infectious diseases

RNA Technology

Bacterial vaccines

Veterinary Vaccines

Cancer Vaccines & Immunotherapies

Bioprocessing & Manufacturing

Clinical Trial/Vaccine Safety

Market Access/Regulatory/International Partnership

Adjuvant, Formulation, and Delivery Technologies

Global Health and Disease Prevention


数据

微信截图_20240621155632.png


会议评价

0734378461808170.png


0734378511808170.png



学术壁报展示

 

 图片1.png



1对1约见系统

图片2.png


联系我们

Sam Li 13482341046

sam.li@chstone-events.com

微信截图_20240718153830.png




演讲嘉宾
  • CEO, DCVMN International, IndiaRajinder Suri
    Rajinder Suri
    CEO, DCVMN International, India
    Rajinder as CEO-DCVMN International is responsible for leadership, governance, strategic vision and overall operational excellence of DCVMN. Rajinder is appointed as member GAVI’s Vaccine Investment Strategy (VIS) Steering Committee 2024, a permanent member of CEPI’s Joint Coordination Group (JCG), 2023-24, member PAVMs Talent Development WS and Regional Vaccine Manufacturing Collaborative (RVMC). To meet an un-precedented challenge posed by COVID-19, Rajinder has been actively involved in all global strategic initiatives along with COVAX partners-WHO, GAVI, CEPI, UNICEF and several other international organizations including industry associations to ensure equitable and timely access to vaccines. He has been member of several advisory expert groups including COVAX Manufacturing & Supply Chain Task Force Leadership Team, G-20 Health Working Group and Market Design and Demand Intelligence pillar of PAVM. Rajinder has over 25 years of top management experience in the industry including at the Board of Directors of the Indian subsidiary of Sanofi Pasteur and as CEO-Panacea Biotec. He has served as Member-GAVI-PPC as well as Vice-President, DCVMN Executive Committee.
  • Chief, Structural Bioinformatics Section National Institutes of Health, USATongqing Zhou
    Tongqing Zhou
    Chief, Structural Bioinformatics Section National Institutes of Health, USA
  • VP, Chinese Preventive Medicine Association; Professor, Jinan University, ChinaXiaofeng Liang
    Xiaofeng Liang
    VP, Chinese Preventive Medicine Association; Professor, Jinan University, China
  • Professor, Director, Viral Pseudotype Unit, University of Kent, UKNigel Temperton
    Nigel Temperton
    Professor, Director, Viral Pseudotype Unit, University of Kent, UK

    Nigel obtained his BSc in Microbiology and Genetics from University College London (UCL) in 1990 and an MSc in Applied Molecular Biology of Infectious Diseases (1992), PhD in Molecular Parasitology (1999) and DLSHTM (2000) from the London School of Hygiene & Tropical Medicine (LSHTM). After his PhD, he returned to UCL as a post-doctoral scientist in the Division of Infection and Immunity. In 2009 Nigel was elected as a member of the highly prestigious Medical Research Club and set up his own research group at the University of Kent. He is currently Chair and Professor in Molecular Virology, Director of the Viral Pseudotype Unit (VPU) and Director of Research and Innovation. Nigel is a Fellow of the Royal Society of Biology (FRSB), Senior Associate Member of the Royal Society of Medicine (RSM), Member of the International Society for Influenza and other Respiratory Virus Diseases (ISIRV), the Microbiology Society and the European Society for Virology (ESV). Nigel acts as external consultant for VisMederi (Italy) and RQbio (UK). He has published over 200 articles with an h-index of 53, >14k citations.


  • Senior Vice President Global Regulatory Affairs,BioNTech, GermanyRuben Rizzi
    Ruben Rizzi
    Senior Vice President Global Regulatory Affairs,BioNTech, Germany

    Ruben Rizzi, physician by training, SVP of Global Regulatory Affairs at BioNTech. I joined the company in December 2019 just before the pandemic, and I have been the global regulatory lead for BioNTech for our COVID-19 development. Currently, I am still supporting the lifecycle of our COVID-19 vaccine, and I am co-leading the Global Regulatory Affairs department at BioNTech and working closely with the teams that are responsible for the development of BioNTech´s pipeline, post-approval activities and labelling


  • Director, The Jenner Institute, Professor, University of Oxford , UKAdrian V. S. Hill
    Adrian V. S. Hill
    Director, The Jenner Institute, Professor, University of Oxford , UK

    Professor Adrian V. S. Hill FRS is the Director and Founder of the Jenner Institute, and Mital Professor of Vaccinology at Oxford University. He is a passionate believer in the power of molecular medicine to address many of the most egregious health care inequities globally. His group have been leaders in the development of adenoviral and other vaccines against infectious diseases and he has tested these in extensively in over eighty clinical trials in Africa and Europe. In partnership with the Serum Institute of India and AstraZeneca the Jenner Institute developed rapidly a ChAdOx1 vector-based SARS-CoV-2 vaccine which saved an estimated 6.2 million lives in 2021 alone.

    His lab also designed a newly licensed high efficacy malaria vaccine, R21/Matrix-MTM, which has recently shown unprecedented high efficacy in a phase III trial in four African countries, again in partnership with the Serum Institute of India and also Novavax Inc. This vaccine promises to make a major impact on reducing the 500,000 childhood deaths from malaria each year. In 2021 he was elected a Fellow of the Royal Society and is a Knight Commander of the Order of the British Empire (KBE).


  • CSO, PATH, USAMelanie Saville
    Melanie Saville
    CSO, PATH, USA

    Melanie Saville, MBBS, is PATH’s Chief Scientific Officer. She leads PATH’s product development division, which includes a global team dedicated to the development, introduction, and scale of vaccines, medical devices, and diagnostics.

    Dr. Saville is a distinguished physician specializing in virology with more than two decades of experience developing and licensing vaccines for global use. Her contributions over the past 20 years have included the development of vaccines for seasonal and pandemic influenza, as well as pediatric combinations and vaccines against rabies, Japanese encephalitis, dengue, Ebola, and SARS-CoV-2.

    Before joining PATH, Dr. Saville worked with the Coalition for Epidemic Preparedness Innovations (CEPI), where she served as the Executive Director of Vaccine Research and Development, leading technical teams supporting vaccine development. She also served as the R&D and manufacturing workstream leader for COVAX, part of a global collaboration to speed development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

    Dr. Saville holds a medical degree, a master’s degree in medical virology, and a Bachelor of Science in molecular biology from University College, London.


  • Former Director, China CDC; Professor, Zhejiang UniversityGeorge Fu Gao
    George Fu Gao
    Former Director, China CDC; Professor, Zhejiang University
  • Unit Head, Local Production & Assistance Unit, Innovation and Emerging Technologies Department (IET),MHP, World Health Organization, SwitzerlandJicui Dong
    Jicui Dong
    Unit Head, Local Production & Assistance Unit, Innovation and Emerging Technologies Department (IET),MHP, World Health Organization, Switzerland
  • SVP of R&D, Global Biologics, Zoetis, USAMahesh Kumar
    Mahesh Kumar
    SVP of R&D, Global Biologics, Zoetis, USA
  • Chief Development Officer, Bharat Biotech, IndiaRaches Ella
    Raches Ella
    Chief Development Officer, Bharat Biotech, India
  • President of Global Business, SK Bioscience, South KoreaHun Kim
    Hun Kim
    President of Global Business, SK Bioscience, South Korea
  • Professor, The Pirbright Institute, UKSimon Graham
    Simon Graham
    Professor, The Pirbright Institute, UK
    I am a veterinary immunologist with an interest in understanding mechanisms of protective immunity and its application to vaccine development. My early career focussed on parasitic diseases, I developed a natural cattle model for testing vaccines against onchocerciasis (river blindness), which provided the first proof-of-principle for vaccine-induced protection. I identified and evaluated vaccine candidate antigens from the apicomplexan parasite Theileria parva, which were designed to induce protective bovine CD8 T cell responses. More recently, my research has focussed on porcine viruses, such as classical swine fever (CSFV) and porcine reproductive and respiratory syndrome (PRRSV) viruses. I informed discussions on the use of emergency vaccination to control future CSF outbreaks by demonstrating that live attenuated CSFV prevented transmission of divergent CSFV strains after only 3 days. I showed that this rapid protection was associated with broadly reactive CD8 T cell responses, opening new avenues to develop DIVA vaccines for outbreak settings. For PRRSV, I contributed to the study of the enhanced pathogenicity of Eastern European strains, highlighting the threat these viruses pose; and contributed to vaccine development efforts through the identification of conserved T cell antigens. My current research is largely focussed on PRRSV and we are pursuing complimentary approaches to improved vaccine development. I am also leading research aimed at developing a Nipah virus vaccine for pigs and supporting COVID-19 vaccine development by using the pig as a preclinical model for assessing immunogenicity of vaccine candidates.
  • Co-founder& CSO, VisMederi, ItalyEmanuele Montomoli
    Emanuele Montomoli
    Co-founder& CSO, VisMederi, Italy
    Emanuele Montomoli was graduated in Life Sciences at University of Siena in 1997. Since November 2016 he was appointed by the Department of Molecular Medicine of University of Siena as full Professor on Public Health. Since April 2018 to 2021 he was nominated in the Executive Board of the Toscana Life Sciences Foundation. Since 2010 he he was elected as President of the Board for the “Master in vaccinology and drug development” at University of Siena. Since 2019 he was nominated in the Executive Board of Eurocine vaccines AB. In 2008 he funded VisMederi srl, an enterprise involved in laboratory activities for vaccines and antiviral drugs clinical trials. Actually, he has a role of Chief Scientific Officer in VisMederi srl. Since 1994 he has carried out epidemiological research, surveillance networks for infectious diseases and serological assays for clinical trials for vaccines. In 2015 he was appointed as scientific coordinator for a project funded by EU-IMI (Innovative Medicine Initiative) titled “Standardization and development of assays for assessment of influenza vaccine correlates of protection”. He is the author of more than 200 papers, as well as numerous abstracts and letters, published in international scientific journals.
  • Adjunct Professor of Medicine, Johns Hopkins Medical SchoolGeorge Siber
    George Siber
    Adjunct Professor of Medicine, Johns Hopkins Medical School

    Dr. Siber is an infectious disease trained physician with more than 40 years of experience in developing vaccines and antibody products. From 1996 to 2007, Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (now Pfizer) where he led the development and approval of multiple innovative childhood vaccines, including Prevenar 7 and 13, the first pneumococcal conjugate vaccines,  Rotashield, the first rotavirus diarrhea vaccine, Meningitec, the first meningococcal meningitis conjugate vaccine and FluMist, the first nasal influenza vaccine. Prior to Wyeth, Dr. Siber was Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute and Director of the Massachusetts Public Health Biologic Laboratories where he developed multiple vaccines and immune globulins, including Respigam, the first antibody licensed for respiratory syncytial virus. Dr. Siber most recently was a Co-founder and Board Member of Affinivax which developed a 24 valent pneumococcal vaccine and was acquired by GSK in 2022. Dr. Siber currently serves on the Scientific Advisory Boards of AdVaccine, CanSino, Clover, Everest Medicines, ILiAD, Valneva, Vaxart and Vaxxinity and has been a consultant to the NIH, EU, WHO and the Gates Foundation. Dr.Siber was member of the Board of  Trustees of the International Vaccine Institute. Dr Siber has received multiple awards including the 2016 Albert Sabin Gold Medal in vaccinology. Dr. Siber holds an MD degree from McGill University in Canada, received post‑doctoral training in Internal Medicine at Rush‑Presbyterian Hospital in Chicago and Beth Israel Hospital in Boston and training in Infectious Diseases and Vaccinology at Boston Children’s Hospital and Beth Israel Hospital, Harvard Medical School.



  • Professor, Chonnam National University Medical School, South KoreaJoon Haeng Rhee
    Joon Haeng Rhee
    Professor, Chonnam National University Medical School, South Korea

    Dr. Joon Haeng Rhee is a graduate of Chonnam National University Medical School and received PhD from the same university. He has been working on molecular microbial pathogenesis and vaccine biology for more than 30 years. His team was the first reporter of the whole genome sequence of V. vulnificus, which became one of the most widely used standard strains in the Vibrio research field. Vaccine study was first started aiming the high mortality V. vulnificus infections. During the vaccine research, his team came across the finding that a flagellin protein of V. vulnificus has an excellent mucosal adjuvant activity in late 1990s. Now flagellin is applied to the development of effective vaccines and immunotherapeutics against diverse diseases such as cancers, allergies, and Alzheimer’s disease. He served the president of Korean Vaccine Society (KVS) from 2013 to 2015. He was elected as an ISV Fellow and serves a member of ISV Executive Board. He is currently the director of Clinical Vaccine R&D Center and Combinatorial Tumor Immunotherapy Research Center of Chonnam National University. As of November 2023, he has more than 170 papers published in peer-reviewed journals and named as an inventor on 40 patents.

  • Distinguished Professor, Shenzhen Institute of Advanced Technology, ChinaDiana Boraschi
    Diana Boraschi
    Distinguished Professor, Shenzhen Institute of Advanced Technology, China
    Diana Boraschi is an immunologist that built her experience in academic institutions and industrial settings in her home country (Italy) and abroad (USA, France, Austria, Korea, Brazil). She is Senior Associate Researcher at the Italian National Research Council (where she served as Institute Director) and at the Stazione Zoologica Anton Dohrn in Napoli, Italy, and Academician of the Accademia dei Fisiocritici. She is currently serving as Distinguished Professor at the Department of Pharmacology at the Shenzhen Institute of Advanced Technologies (SIAT) of the Chinese Academy of Sciences, in Shenzhen, China. She is author of over 200 peer-reviewed research articles in immunology (h-index 67, over 16000 citations), in addition to many books and book chapters, and inventor in eight patents. In 2017, she has received an honorary PhD degree by the University of Salzburg (Austria), in 2020 the High-Level Talents Program Award for Foreign Scholars, and in 2022 the Chinese Government Friendship Award. She is listed within the first 2% scientists worldwide since 2017 and in the first 1% since 2020. Her area of expertise is innate immunity and inflammation, in particular in relation to autoimmune, inflammatory and degenerative diseases, and vaccine development. Her focus on macrophages and cytokines of the IL-1 superfamily (a bioactive IL-1 domain is known as the “Boraschi loop”), and the interaction of engineered nanomaterials with immunity in humans and environmental species. She is particularly involved in higher education training activities in Europe, Asia, Africa, and South America, with a focus on poverty-related diseases.
  • Director, International Vaccine Design Center, Professor, University of Tokyo, JapanKen Ishii
    Ken Ishii
    Director, International Vaccine Design Center, Professor, University of Tokyo, Japan

    Prof. Ken J. Ishii, M.D., Ph.D., currently Director for Int. Vaccine Design Center, The Institute of Medical Science, the University of Tokyo, has 27 years of experience in Vaccine R&D since 1998 including 7 years as a IND reviewer at US Food and Drug Administration (FDA), 15 years as a basic immunologist at Osaka University, 9 years as a vaccine adjuvant expert at National Institute (NIBIOHN), 2 years as managing director at AMED (medical funding agency), as well as Advisor for PMDA (regulatory agency), GHIT (global fund) and CEPI. He has contributed to basic research on infectious diseases and immunology, resulted in numerous books and over 250 periodical publications and 35,000 citations with H-index 84 as well as over 50 patents related to vaccine and adjuvant, and to regulation of many vaccines and guidelines for vaccine preclinical and clinical trials in Japan and US.

  • Founder, Vaxine, AustraliaNikolai Petrovsky
    Nikolai Petrovsky
    Founder, Vaxine, Australia
    Professor Nikolai Petrovsky is a physician and vaccine researcher. He is the founder of Vaxine, an Australian biotechnology company applying novel approaches including artificial intelligence to vaccine and adjuvant development. His research has been awarded multi-million dollar contracts from the US National Institutes of Health and he has authored over 200 peer-reviewed research papers. He developed SpikoGen®, a vaccine against COVID-19 that received emergency use authorization in the Middle East in October 2021, making it the first recombinant protein vaccine against COVID-19 to achieve regulatory approval.
  • CEO, Hilleman LaboratoriesRaman Rao
    Raman Rao
    CEO, Hilleman Laboratories

    Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.

    Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.

    He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.


  • SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical, ChinaWei Tan
    Wei Tan
    SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical, China
  • Professor, Lanzhou Veterinary Research Institute, ChinaHuichen Guo
    Huichen Guo
    Professor, Lanzhou Veterinary Research Institute, China

    Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.

    Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.

    He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.


  • Director of International Cooperations, Sinopharm CNBGMeng Li
    Meng Li
    Director of International Cooperations, Sinopharm CNBG

    Meng LI has been leading the International business team of CNBG since 2013, oversees CNBG’s international cooperation and registration activities. She also serves on the board of CNBG-Virogen, and the board of Emerging Biopharmaceuticals Manufacturers Network (EBPMN). During her 19 year experiences in biological industry, she established extensive networks with academia, NGOs, enterprises internationally, and successfully completed a number of landmark projects. Including the bOPV capacity expansion and prequalification program with BMGF (received over 23Million USD financial supports from BMGF, prequalified by WHO in 2019), establishment of CNBG’s first JV with foreign enterprise, the first overseas acquisition by CNBG, roll-out of the Covid-19 vaccine PhIII trials in 6 countries and its registration in over 100 countries. Meng Li has successfully signed a number of in-license, research cooperation, commercialization and industrialization projects with NIH, Oxford, France Institut Pasteur, PATH, IVI, biotech companies and developing country manufacturers. She worked as temporary advisor to WHO inspectorate during WHO’s first inspection to China NMPA in 2010, and was elected as the executive committee member of DCVMN from 2014-2016.


  • Chief Scientific Adviser, AdvaccineBin Wang
    Bin Wang
    Chief Scientific Adviser, Advaccine

    Dr. Bin Wang is the Co-founder, Chairman of Advaccine Biotechnology Co LTD. He is also holding a distinguished professor position at the Fudan University School of Basic Medical Sciences and serves as the chairman for the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulations. He has developed novel adjuvants and recombinant vaccines, novel DNA vaccine delivery, and led to several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute in 1992 in Philadelphia. He became an instructor and assistant professor at the University of Pennsylvania Medical School from 1993 to 1998. He was a professor and served as the Chairman of the Department of Microbiology and Immunology for six years at the College of Biological Sciences, China Agricultural University before he joined Fudan University. He was one of the very early DNA vaccine technology inventors in the 90’s and performed the first-in-human DNA vaccine trials in 1994-1996. He has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections in recent years and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published over 160 peer-review articles and awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and executive member in several professional societies.

  • Professor, Tsinghua UniversityLinqi Zhang
    Linqi Zhang
    Professor, Tsinghua University
    Professor Linqi Zhang is the Director of the Comprehensive AIDS Research Center at Tsinghua University. Prof. Zhang's research focuses on HIV-1 pathogenesis and vaccine development, and has recently expanded to the field of emerging and re-emerging human viral pathogens such as SARS-CoV-1/2 and MERS-CoV. Using cutting-edge antibody and combinatorial antigen library techniques, Prof. Zhang’s research aims to characterize protective antibody immunity in infected humans and rational design of effective vaccines and therapies against the viral infection. Professor Zhang is the recipient of the National Outstanding Young Scientist Award, privileged Changjiang Professorship, and Bayer and Vanke Chair professor. He has published extensively and is among the most cited Chinese researchers in the field of microbiology and immunology. Professor Zhang has also served as a member of national expert and advisory board to the Chinese government and several international organizations on HIV/AIDS and infectious diseases,and was recently elected as a Foreign Fellow of the African Academy of Sciences.
  • Professor, Xiamen UniversityShaowei Li
    Shaowei Li
    Professor, Xiamen University

    Shaowei Li Ph.D. Professor of Biochemistry and Structural Vaccinology, Xiamen University Shaowei Li is a tenured Professor of Biochemistry and Structural Vaccinology in the School of Life Sciences with a joint appointment in the School of Public Health, Xiamen University, China. He is the vaccine group leader in the National Institute of Diagnostics and Vaccine Development in infectious diseases (NIDVD), one of the academic leaders in the State Key Laboratory of Molecular Vaccinology and Diagnostics, deputy director in Fujian provincial Xiang An biomedicine laboratory. Dr. Li has inter-disciplinary research interests focusing on structural vaccinology, resulting in more than 120 peer-reviewed papers. He also has translational experience in vaccine development against infectious diseases—such as Hepatitis E vaccine and HPV vaccine, especially in aspects of immunogen design, process development and antigen characterization. Dr. Li has won two of China’s National Science and Technology Awards and been listed in the Top 20 translational researchers of 2016, ranked by Nature Biotechnology. He has served on the Product Development for Vaccines Advisory Committee (PDVAC), World Health Organization (WHO) since 2022.

  • Director of Chula Vaccine Research Center, Chulalongkorn UniversityKiat Ruxrungtham
    Kiat Ruxrungtham
    Director of Chula Vaccine Research Center, Chulalongkorn University
    Kiat Ruxrungtham, is a Professor of Medicine, Department of Medicine , Faculty of Medicine, Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC); and Director of the Covid19 Vaccine Development Program, ChulaVRC. He is providing teaching and patient care on Allergy -Clinical Immunology and HIV Medicine at the King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University; and is mentoring junior researchers on HIV medicine at HIVNAT, TRCARC; vaccine and Immunology (at Chula Vaccine Research Center); and also on clinical trials. He is currently leading the Chula-Covid19 mRNA vaccine development program at ChulaVRC. Honors: He has received several awards: 2006 Outstanding Internist Award on Medical Academy, Royal College of Physicians, Thailand 2007 Outstanding Researcher Award, and the Highest Citation Award, Chulalongkorn University, Bangkok, Thailand 2011 Senior Research Scholar Award, the Thailand Research Fund 2011 Outstanding Researcher Award, National Research Council, Thailand 2015 Senior Research Scholar Award, the Thailand Research Fund 2015 Outstanding Research Award, the Thailand Research Fund 2022 A Royal Award “Contributors to the development of the country’s vaccines” from Her Royal Highness Princess Maha Chakri Sirindhorn at the 10th Vaccination Conference Publications: He has published more than 370 peer review papers on HIV, immunology, allergy, and vaccine. Contributions to national and international academics and professional organization: 1. Former President of the Allergy, Asthma and Immunology Association, Thailand (AAIAT) 2. Former President of the Thai AIDS Society (TAS) 3. Co-chair of the Co-chair of the APAACI and APAAAPARI 2018, Bangkok, Thailand 4. Co-chair of the World Allergy Congress 2023, Bangkok, Thailand 5. Chief-editor, Asian Pacific Journal of Allergy and Immunology (APJAI)
  • Professor, Fudan University, ChinaShibo Jiang
    Shibo Jiang
    Professor, Fudan University, China
    Dr. Shibo Jiang is a Professor at the Shanghai Institute of Infectious Disease and Biosecurity of Fudan University, Shanghai, China. His main research interest is the development of antiviral drugs and vaccines. He has published 572 papers (total IF: 7,662, average IF: 13.4) in SCI journals such as Cell (x3), Nature (x2), Science (x2), Lancet (x4), CNS’ sister journals (x71), with total 45,327 citations and an h-index of 105. He has applied for 104 patents, 54 of which were issued, and 11 of them were licensed out with 3 classes of innovative drugs and medical products used in clinics.
  • Co-Founder & General manager Emerging markets,Gennecs Holding, EgyptNibal Dahaba
    Nibal Dahaba
    Co-Founder & General manager Emerging markets,Gennecs Holding, Egypt
  • Professor, The Pirbright Institute, UKChristopher Netherton
    Christopher Netherton
    Professor, The Pirbright Institute, UK
  • President, Vaccine Division, Fosun PharmaJiguo Zhang
    Jiguo Zhang
    President, Vaccine Division, Fosun Pharma

    Graduated from Peking University School of Medicine, and National School of Development at Peking University, Jeffrey Zhang has deep insights in the fields of vaccines, while having extensive experience in business management, strategy and investment. He has successively served as the head of Pfizer’s New Business Development in China, General Manager of Emerging Business Department of GSK China/Vice President of Emerging Market Strategy, as well as the Vice President of Strategy of WuXi/Vice President of WuXi Vaccine Business.

  • Head, Local Production and Assistance Unit Regulation & PQ, Access to Medicines and Health Products Division,WHO, SwitzerlandJicui Dong
    Jicui Dong
    Head, Local Production and Assistance Unit Regulation & PQ, Access to Medicines and Health Products Division,WHO, Switzerland
  • Director General, Vaccine Innovative Technology ALliance (VITAL)-KoreaBaik-Lin Seong
    Baik-Lin Seong
    Director General, Vaccine Innovative Technology ALliance (VITAL)-Korea

    Baik-Lin Seong, PhD, is a Distinguished Professor of Yonsei University College of Medicine, and Director General of Vaccine Innovative Technology ALliance (VITAL)-Korea. He received B.S. from Seoul National University (1977), M.S. from KAIST (1979), PhD from MIT (1988). He worked as postdoctoral scientist at the University of Oxford (1988-1992).

    He served as a member of the Presidential Advisory Council of Science & Technology of Korean Government (2021-2022) and the Scientific Advisory Board of International Vaccine Institute (IVI) (2018-2022). He chaired the COVID-19 Vaccine Pan-Government Strategic Plan of the Korean Government (2020-2023).

    With a view to ensure equitable access of effective vaccines to LMICs, he works on developing a low-cost production platform of VLP/nanoparticle vaccines against RSV, norovirus, nipah, universal influenza vaccine, and flavivirus vaccines including Japanese Encephalitis, Zika, and West Nile viruses.


  • CEO, Afrigen Biologics, South AfricaPetro Terblanche
    Petro Terblanche
    CEO, Afrigen Biologics, South Africa
    Professor Petro Terblanche has a successful track record in the strategic and operational management of technology intensive organizations. She has played a key part in the design and implementation of South Africa’s biotechnology strategy. She holds the position of Chief Executive Officer of Afrigen Biologics (Pty)Ltd based in Cape Town, South Africa. Afrigen hosts the WHO Global mRNA technology development and transfer Hub and has a mRNA Covid 19 vaccine candidate in development as part of a global program to build capacity and capabilities in LMICs to design, develop and produce mRNA vaccines. Prof Terblanche is the author of more than 200 scientific publications and conference papers in public health. Petro holds several Board positions and serves on a number of scientific advisory boards in the public health sector. She was recently acknowledged as one of the legends of science by the Academy of Sciences South Africa.
  • Head of Development China, General Manager of China R&D, PfizerZhaohua Jessie Chen
    Zhaohua Jessie Chen
    Head of Development China, General Manager of China R&D, Pfizer
  • VP, Translational Science, BioNTech/ CEO, VaxxCellenceRobbert van der Most
    Robbert van der Most
    VP, Translational Science, BioNTech/ CEO, VaxxCellence

    Dr Robbert van der Most obtained his cum laude PhD in 1994 at Leiden University (Netherlands) on the topic of coronavirus molecular biology. He then conducted postdoctoral work on the immunology of chronic viral infection with Dr Rafi Ahmed(UCLA, Eiory University, USA) and flavivirus molecular biology with Dr Jim Strauss (Caltech, USA). Upon return to the Netherlands he worked on RSV vaccine immunology, focusing on the mechanisms of vaccine-enhanced disease. In 2004, he joined Dr Bruce Robinson's team at the University of Western Australia to study immune oncology and the immune-modifying effects of chemotherapy. In 2008, he joined GSK Vaccines in Belgium, in roles of increasing responsiblility, leadingTranslational Science, After a brief period at CEPl, he joined BioNTech as Vice-President Translational Science in 2022, leading a team of experts in the infectious disease portfolio, in 2024 he started his own consultancy business, aiming to provide scjentific and development advice to biotech and pharma companies, as well as not-for-profit organizations.

  • Deputy Department Head, Jiangsu CDC, ChinaJingxin Li
    Jingxin Li
    Deputy Department Head, Jiangsu CDC, China

    Jingxin Li, PhD, Professor, is working at Jiangsu Provincial Center for Disease Control and Prevention. Her research is focused on vaccine clinical evaluation and immunization strategy. She has participated in a lot of epidemiology investigations and a series of clinical trials of novel vaccines, including Enterovirus type 71 vaccine, recombinant human Ad5 vectored Ebola vaccine, and Covid-19 vaccines. She has got National Natural Science Outstanding Youth Founds and Jiangsu Provincial Natural Science Funds for Distinguished youths, and hosted or participated in seven National Natural Science Founds or National Science and Technology Major Projects. She has published over 25 articles in medical journals on vaccine clinical studies, including Nature Med, Lancet Respir Med, Lancet Glob Health, etc.


  • Director, Institute of Pathogen Biology, CAMS & PUMCYuelong Shu
    Yuelong Shu
    Director, Institute of Pathogen Biology, CAMS & PUMC

    Prof. Yuelong Shu

    Director, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College. He is a member of the Chinese Academy of Medical Sciences and a Fellow of the American Academy of Microbiology. He was selected as the first batch of ‘National Science and Technology Innovation Leader’and‘2014 Top Ten Scientific and Technological Innovators’, and is the winner of National Science Fund for Distinguished Young Scholars and the China Youth Science and Technology Award. He has been honored with the National Science and Technology Progress Grand Prize, First Prize, Second Prize, the National Medical and Health System Advanced Individual, the National Innovation Award, the Public Health and Preventive Medicine Development Contribution Award, etc. He is currently the Chairman of the Branch of Medical Virology of the Chinese Medical Association and the Chairman of the Asia-Pacific Alliance for the Control of Influenza (APACI). He was the founding dean of the School of Public Health of Sun Yat-sen University (Shenzhen), the editor-in-chief of the Chinese Journal of Virology, the deputy director of the Institute of Viral Diseases of the Chinese Center for Disease Control and Prevention (CDC), the director of the National Influenza Center, and the director of the WHO Collaborating Center for Reference and Research on Influenza.

    Shu has long focused on influenza prevention and control research, and has made outstanding achievements in the discovery of new viruses, the development of detection reagents, and the pathogenesis of infection. Through the systematic establishment of new influenza detection and surveillance technology, it was found for the first time in the world that a variety of new avian influenza viruses such as H7N9, H5N6 and H10N8 can lead to human infection and death; The first successful development of pandemic H1N1 2019 and H7N9 avian influenza detection reagent; The origin, evolution and infection mechanism of H7N9 and other avian influenza viruses were clarified, which provided key scientific and technological support for the successful prevention and control of the epidemic in China. He has published nearly 200 papers in Science, Nature, NEJM, Lancet and other academic journals as a corresponding author. The research results were selected as one of the ‘China’s 100 most influential international academic papers in 2013’and ‘2013 Top Ten Scientific Advances in China’.


  • Professor, Duke-NUS Medical School, SingaporeLinfa Wang
    Linfa Wang
    Professor, Duke-NUS Medical School, Singapore

    Dr. Linfa Wang is a professor of the Programme in Emerging Infectious Diseases at Duke-NUS Medical School, and the inaugural executive director of PREPARE, Ministry of Health, Singapore. He is an international leader in the field of emerging zoonotic viruses and virus-host interaction. In response to the COVID-19 pandemic, he has served and is serving on multiple WHO committees for COVID-19, including the WHO IHR Emergency Committee. Prof. Wang has more than 500 scientific publications. He was the Editor-in-Chief for the Virology Journal from 2112-2022. Prof. Wang was elected to the Australian Academy of Technological Sciences and Engineering in 2010, the American Academy of Microbiology in 2021 and the Australian Academy of Sciences in 2023. He received the Singapore President Science Award in 2021

  • Chief Science Advisor, Africa Centres for Disease Control and Prevention, EthiopiaNicaise Ndembi
    Nicaise Ndembi
    Chief Science Advisor, Africa Centres for Disease Control and Prevention, Ethiopia
    Dr. Nicaise Ndembi is Senior strategic Advisor on Sciece and Policy to the Africa Centres for Disease Control and Prevention Director General and currently Associate Professor, Division of Epidemiology and Prevention at the Institute of Human Virology (IHV), University of Maryland School of Medicine, Baltimore, USA. Dr. Ndembi is a graduate of Kanazawa University School of Medicine, Department of Viral Infection and International Public Health, Japan and a Research Professor within the same Institution. He is a Principal Investigator on numerous grants including US National Health Institute (NIH). He has authored/co-authored more than 180 publications in peer-reviewed journals. He is the Editor-in-Chief of the Journal of Public Health in Africa (JPHIA), AIDS Research and Therapy (ARTY), and serves on various WHO and US NIH Advisory Groups.
  • Yunlong Cao, Peking UniversityYunlong Cao
    Yunlong Cao
    Yunlong Cao, Peking University

    曹云龙,北京大学生物医学前沿创新中心(BIOPIC)研究员、助理教授,北大-清华生命科学联合中心研究员,北京昌平实验室领衔科学家,国家优秀青年科学基金获得者。2014年毕业于浙江大学竺可桢学院物理学专业,2019年获得哈佛大学化学博士学位。在新冠疫情期间,他围绕新冠病毒B细胞免疫应答、特异性抗体的结构与功能等开展了系统性研究,其中新冠中和抗体药物研制、新冠体液免疫响应特征和新冠突变免疫逃逸机制的创新性研究结果为抗击疫情做出了突出贡献。以第一作者、通讯作者在Nature、Cell、The Lancet Infectious Diseases、Cell Host & Microbe等期刊上发表多篇相关研究文章。相关研究成果获评2022年度“中国科学十大进展”、2022年度“中国生命科学十大进展”。其本人受邀作为WHO新冠疫苗成分技术咨询小组(TAG-CO-VAC)成员、国际流行病防范创新联盟(CEPI)科学顾问,获评2022年度北京市杰出青年中关村奖、《麻省理工科技评论》中国区“35岁以下科技创新35人”、2022年度Nature十大人物,获得国家优秀青年科学基金资助。


  • Professor, Harvard Medical SchoolDan Barouch
    Dan Barouch
    Professor, Harvard Medical School
  • 活动门票
    活动筹备中
    售票推广中
    活动结束
    选择票
    门票名称
    单价(¥ )
    截止时间
    数量
    早早鸟票
    1,580
    2024-09-20 23:55
    0
    此门票含3天午餐,1张会议门票、会议资料及一对一约见系统账户
    票价
    0